BONUS ZERTIFIKAT - NOVO-NORDISK B | Market Closed - Bid/Ask 03:28:07 2024-07-12 pm EDT | ||
| 98.98 EUR | +2.02% |
|
| Current month | -0.82% | ||
| 1 month | -1.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 98.98 | +2.02% |
| 24-07-11 | 97.02 | -2.08% |
| 24-07-10 | 99.08 | +0.92% |
| 24-07-09 | 98.18 | -1.26% |
| 24-07-08 | 99.43 | +0.39% |
Real-time Boerse Frankfurt Warrants
Last update July 12, 2024 at 03:28 pm EDT
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW914A |
| ISIN | DE000SW914A5 |
| Date issued | 2024-05-08 |
| Strike | 975 kr |
| Maturity | 2025-06-20 (343 Days) |
| Parity | 10 : 1 |
| Emission price | 87.33 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 104.4 € |
|---|---|
| Lowest since issue | 89.43 € |
| Spread | 1.83 € |
| Spread % | 1.81% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
967.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-1.11%
- Stock Market
- Certificates
- Certificat
